目的 基于网状Meta分析方法，比较不同益气活血类中成药在脑梗死恢复期治疗方面的差异。方法 系统检索国内外中国知网、万方、维普、PubMed、Cochrane、EMbase等数据库，检索时限为自建库至2021年2月。查重筛选后，2名作者背对背提取文献资料，并采用Cochrane偏倚风险评估工具评价文献质量，采用Stata 16和GeMTC 14.3进行网状Meta分析。结果 最终纳入45项研究，4355例患者，涉及6种益气活血类中成药。网状Meta分析显示，在改善总有效率方面，概率排序为脑心通胶囊＋西医常规治疗（0.59）>复方地龙胶囊/片＋西医常规治疗（0.18）>消栓肠溶胶囊＋西医常规治疗（0.09）>灯盏生脉胶囊＋西医常规治疗（0.08）>脑脉泰胶囊＋西医常规治疗（0.06）>通心络胶囊＋西医常规治疗（0.00）>西医常规治疗（0.00）；在降低神经功能评分方面，概率排序为消栓肠溶胶囊＋西医常规治疗（0.67）>通心络胶囊+西医常规治疗（0.21）>复方地龙胶囊/片＋西医常规治疗（0.06）>脑心通胶囊＋西医常规治疗（0.03）>灯盏生脉胶囊＋西医常规治疗（0.02）>脑脉泰胶囊＋西医常规治疗（0.01）>西医常规治疗（0.00）；在提高日常生活能力评分方面，概率排序为消栓肠溶胶囊＋西医常规治疗（0.60）>脑心通胶囊＋西医常规治疗（0.29）>通心络胶囊＋西医常规治疗（0.07）>复方地龙胶囊/片＋西医常规治疗（0.04）>灯盏生脉胶囊＋西医常规治疗（0.01）>西医常规治疗（0.00）。结论 不同益气活血类中成药联合西医常规治疗在脑梗死恢复期的疗效方面均优于单用西医常规治疗，但因各中成药在不同结局指标中疗效排序差异较大，且纳入文献质量不高，故尚需开展大规模、高质量临床研究。

Objective To compare the clinical efficacy of different Yiqi Huoxue Chinese patent medicines in the treatment of recovery period of cerebral infarction (CI) by network Meta-analysis. Methods Domestic and foreign databases including CNKI, Wanfang, VIP, PubMed, EMbase, Cochrane Library were systematically searched from inception to February 2021. Two authors independently extracted the literature data and evaluated the quality of literatures. Then Stata 16 and GeMTC 14.3 were used for network Meta-analysis. Results Finally, 45 studies and 4355 cases were included, involving six kinds of Yiqi Huoxue Chinese patent medicines. The results of the Meta-analysis showed that in terms of improving total effective rate, the probability order was Naoxintong Capsule (脑心通胶囊) + western medicine treatment (0.59), Fufang Dilong Capsule/Tablet (复方地龙胶囊/片) + western medicine treatment (0.18), Xiaoshuan Changrong Capsule (消栓肠溶胶囊) + western medicine treatment (0.09), Dengzhan Shengmai Capsule (灯盏生脉胶囊) + western medicine treatment (0.08), Naomaitai Capsule (脑脉泰胶囊) + western medicine treatment (0.06), Tongxinluo Capsule (通心络胶囊) + western medicine treatment (0.00), western medicine treatment (0.00); in terms of decreased neurological function score, the probability order was Xiaoshuan Changrong Capsule + western medicine treatment (0.67), Tongxinluo Capsule + western medicine treatment (0.21), Fufang Dilong Capsule/tablet + western medicine treatment (0.06), Naoxintong Capsule + western medicine treatment (0.03), Dengzhan Shengmai Capsule + western medicine treatment (0.02), Naomaitai Capsule + western medicine treatment (0.01), western medicine treatment (0.00); in terms of improving the ability to live daily, the probability order was Xiaoshuan Changrong Capsule + western medicine treatment (0.60), Naoxintong Capsule + western medicine treatment (0.29), Tongxinluo Capsule + western medicine treatment (0.07), Fufang Dilong Capsule/tablet + western medicine treatment (0.04), Dengzhan Shengmai Capsule + western medicine treatment (0.01), western medicine treatment (0.00). Conclusion Although the clinical efficacy of different Yiqi Huoxue Chinese patent medicines combined with western medicine treatment is superior to western medicine treatment alone in the treatment of recovery period of cerebral infarction, large-scale high-quality clinical studies are still needed due to the large difference in efficacy ranking among different outcome indicators of Yiqi Huoxue Chinese patent medicines and the low quality of included literature..

R285.64

“十三五”国家重点研发计划（2018YFC1705000，2018YFC1705001）